Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients

BACKGROUND. The PD-1–blocking antibody nivolumab persists in patients several weeks after the last infusion. However, no study has systematically evaluated the maximum duration that the antibody persists on T cells or the association between this duration and residual therapeutic efficacy or potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Osa, Akio, Uenami, Takeshi, Koyama, Shohei, Fujimoto, Kosuke, Okuzaki, Daisuke, Takimoto, Takayuki, Hirata, Haruhiko, Yano, Yukihiro, Yokota, Soichiro, Kinehara, Yuhei, Naito, Yujiro, Otsuka, Tomoyuki, Kanazu, Masaki, Kuroyama, Muneyoshi, Hamaguchi, Masanari, Koba, Taro, Futami, Yu, Ishijima, Mikako, Suga, Yasuhiko, Akazawa, Yuki, Machiyama, Hirotomo, Iwahori, Kota, Takamatsu, Hyota, Nagatomo, Izumi, Takeda, Yoshito, Kida, Hiroshi, Akbay, Esra A., Hammerman, Peter S., Wong, Kwok-kin, Dranoff, Glenn, Mori, Masahide, Kijima, Takashi, Kumanogoh, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237460/
https://www.ncbi.nlm.nih.gov/pubmed/30282824
http://dx.doi.org/10.1172/jci.insight.59125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237460/
https://www.ncbi.nlm.nih.gov/pubmed/30282824
http://dx.doi.org/10.1172/jci.insight.59125

Ejemplares similares